Literature DB >> 21610686

Update on bone-modifying agents in metastatic breast cancer.

Larry J Suva1, Brooke E Brander, Issam Makhoul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21610686     DOI： 10.1038/nrendo.2011.80

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

Review 2.  Bone metastasis: mechanisms and therapeutic opportunities.

Authors:  Larry J Suva; Charity Washam; Richard W Nicholas; Robert J Griffin
Journal:  Nat Rev Endocrinol       Date:  2011-01-04       Impact factor: 43.330

3.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; L Porter; D Blayney; A Lipton; C Sinoff; H Wheeler; J F Simeone; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

4.  Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

5.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

6.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

Authors:  Bruce E Hillner; James N Ingle; Rowan T Chlebowski; Julie Gralow; Gary C Yee; Nora A Janjan; Jane A Cauley; Brent A Blumenstein; Kathy S Albain; Allan Lipton; Susan Brown
Journal:  J Clin Oncol       Date:  2003-09-08       Impact factor: 44.544

7.  Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Authors:  Allan Lipton; Richard J Cook; Pierre Major; Matthew R Smith; Robert E Coleman
Journal:  Oncologist       Date:  2007-09

8.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

9.  Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.

Authors:  Jean-Jacques Body; Allan Lipton; Julie Gralow; Guenther G Steger; Guozhi Gao; Howard Yeh; Karim Fizazi
Journal:  J Bone Miner Res       Date:  2010-03       Impact factor: 6.741

10.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245
  10 in total
  5 in total

Review 1.  Hallmarks of Bone Metastasis.

Authors:  Rachelle W Johnson; Larry J Suva
Journal:  Calcif Tissue Int       Date:  2017-11-14       Impact factor: 4.333

2.  Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis.

Authors:  Charity L Washam; Stephanie D Byrum; Kim Leitzel; Suhail M Ali; Alan J Tackett; Dana Gaddy; Suzanne E Sundermann; Allan Lipton; Larry J Suva
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

Review 3.  The best of both worlds - managing the cancer, saving the bone.

Authors:  Issam Makhoul; Corey O Montgomery; Dana Gaddy; Larry J Suva
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

Review 4.  Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.

Authors:  Demetrios Simos; Christina L Addison; Iryna Kuchuk; Brian Hutton; Sasha Mazzarello; Mark Clemons
Journal:  J Clin Med       Date:  2013-08-19       Impact factor: 4.241

5.  Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.

Authors:  Juan Li; Qianying Pan; Patrick D Rowan; Timothy N Trotter; Deniz Peker; Kellie M Regal; Amjad Javed; Larry J Suva; Yang Yang
Journal:  Oncotarget       Date:  2016-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.